World of DTC Marketing

MAY 26, 2021

net revenue for Imbruvica has increased from $492 million in 2014 to $4.3 billion in Imbruvica net revenue from Medicare Part D between 2014 and 2018. AbbVie has obtained or applied for over 250 patents on Humira to block competition from lower-priced biosimilars. AbbVie’s yearly U.S. billion in 2020. billion in 2020.

Competition 180

Competition Marketing Government Patients 180

pharmaphorum

DECEMBER 15, 2022

A pharma industry organisation has warned that record levels of revenue clawback from the UK government is threatening “footprint, R&D and manufacturing investments” in the country. Next year we must start again with a clean sheet of paper to agree on what an internationally competitive scheme looks like.”

Pharma 73

Pharma Government Manufacturing Medicine 73

pharmaphorum

SEPTEMBER 5, 2022

The UK Competition and Markets Authority (CMA) is seeking to disqualify Peter Butterfield, currently chief executive of Alliance Pharma, from serving as a company director. ” The action will only be heard if the Competition Appeal Tribunal (CAT) upholds the CMA’s findings against Alliance, it added. .”

Pharma 59

Pharma Competition Management Marketing 59

pharmaphorum

OCTOBER 5, 2022

This time last year, the pharma giant published two whitepapers on the topic, setting out proposed frameworks for valuing combination treatments and for compliant inter-organisation arbitration. This access conundrum was acknowledged by NICE as far back as 2014, and has been sitting in pharma’s “inbox” for some time.

Medicine 98

Medicine Competition Patients Marketing 98

pharmaphorum

OCTOBER 10, 2022

Copaxone was a mainstay of Teva’s portfolio which the Israel-based pharma fought hard to protect, including releasing a long-acting version to counter cheaper copycat drugs. It was a $4 billion-a-year blockbuster at its peak in 2014, but shrank to around $1 billion last year and is predicted to make around $700 million this year. .

Competition 52

Competition Marketing Medicine Pharma 52

pharmaphorum

JANUARY 16, 2023

Two top pharma companies have exited the UK’s voluntary medicines pricing agreement in protest at what the industry has said is a “punitive” system of revenue clawbacks, casting doubt on the future of the scheme in its present form. in 2022. .

Government 69

Government Medicine Consulting Management 69

pharmaphorum

JANUARY 27, 2023

While global macroeconomic uncertainty continues to impact financing, the pharma industry has focused on UK biotechs to strengthen product pipelines. There is global capital out there for us to attract, as well as finance in the City of London [that] we need to unlock, but competition is fierce.”

Pharma 52

Pharma Manufacturing Medicine Biopharma 52